Stonebridge Herald today published a report detailing the FDA's October 5, 2026 request for public input on how early-phase clinical trials of ibogaine drug products should be designed, a move tied to a presidential directive on psychedelic medicine and ongoing safety concerns about the compound.
The Herald's coverage outlines the FDA's four focus areas for comment, including dose selection with a proposed starting dose not exceeding 10 mg/kg, safety monitoring for cardiac and neurologic events, eligibility criteria, and ethical oversight. The report also details the 45-day comment period under Docket No. FDA-2026-N-10429, closing November 20, 2026.
Additionally, the report examines how this request fits into broader federal action, including HHS funding through ARPA-H and NIDA, and the prioritization of research into opioid use disorder and post-traumatic stress disorder populations.
Stonebridge Herald's full report provides additional context on the FDA's guidance history and drug review process relevant to this announcement.
Stonebridge Herald is an independent news publication covering politics, business, technology, and health for readers across the United States.
This page is a syndicated release — full coverage at stonebridgeherald.com